Narwhal Capital Management Boosts Holdings in Abbott Laboratories $ABT

Narwhal Capital Management increased its stake in Abbott Laboratories (NYSE:ABT) by 7.5% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 76,982 shares of the healthcare product maker’s stock after buying an additional 5,386 shares during the period. Narwhal Capital Management’s holdings in Abbott Laboratories were worth $9,645,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Danica Pension Livsforsikringsaktieselskab bought a new stake in shares of Abbott Laboratories during the third quarter valued at approximately $185,640,000. Asset Management One Co. Ltd. lifted its position in Abbott Laboratories by 2.4% in the 3rd quarter. Asset Management One Co. Ltd. now owns 858,834 shares of the healthcare product maker’s stock valued at $115,032,000 after acquiring an additional 19,966 shares in the last quarter. Nordea Investment Management AB boosted its stake in Abbott Laboratories by 6.1% during the 3rd quarter. Nordea Investment Management AB now owns 329,430 shares of the healthcare product maker’s stock valued at $43,785,000 after purchasing an additional 18,974 shares during the last quarter. AE Wealth Management LLC increased its holdings in shares of Abbott Laboratories by 20.8% in the 3rd quarter. AE Wealth Management LLC now owns 65,504 shares of the healthcare product maker’s stock worth $8,774,000 after purchasing an additional 11,264 shares in the last quarter. Finally, Mawer Investment Management Ltd. raised its stake in shares of Abbott Laboratories by 5.9% in the third quarter. Mawer Investment Management Ltd. now owns 1,255,780 shares of the healthcare product maker’s stock worth $168,199,000 after purchasing an additional 70,122 shares during the last quarter. Hedge funds and other institutional investors own 75.18% of the company’s stock.

Insider Activity

In other Abbott Laboratories news, EVP Daniel Gesua Sive Salvadori sold 885 shares of the business’s stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $115.58, for a total transaction of $102,288.30. Following the completion of the sale, the executive vice president owned 146,377 shares of the company’s stock, valued at approximately $16,918,253.66. The trade was a 0.60% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Daniel J. Starks purchased 10,000 shares of Abbott Laboratories stock in a transaction on Monday, April 27th. The stock was bought at an average price of $92.65 per share, with a total value of $926,500.00. Following the transaction, the director owned 6,751,103 shares of the company’s stock, valued at approximately $625,489,692.95. This represents a 0.15% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last 90 days, insiders have purchased 22,200 shares of company stock worth $2,215,100 and have sold 3,055 shares worth $353,097. 0.46% of the stock is currently owned by insiders.

Analyst Ratings Changes

ABT has been the topic of several recent analyst reports. Daiwa Securities Group cut Abbott Laboratories from an “outperform” rating to a “neutral” rating and set a $92.00 price objective on the stock. in a research report on Wednesday, April 22nd. Citigroup lowered their target price on shares of Abbott Laboratories from $136.00 to $108.00 and set a “buy” rating on the stock in a research note on Friday, April 17th. Piper Sandler reduced their price target on shares of Abbott Laboratories from $135.00 to $115.00 and set an “overweight” rating for the company in a research note on Friday, April 17th. Weiss Ratings cut shares of Abbott Laboratories from a “hold (c)” rating to a “hold (c-)” rating in a report on Friday. Finally, Mizuho dropped their target price on shares of Abbott Laboratories from $125.00 to $115.00 and set a “neutral” rating on the stock in a report on Friday, April 17th. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating and five have assigned a Hold rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $119.43.

Abbott Laboratories News Roundup

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Insiders buying: Director Daniel Starks bought 10,000 shares (~$92.65) and CFO Philip Boudreau purchased 2,200 shares (~$91.50). Multiple insider buys (including the CEO earlier) are being read as confidence from management and have supported intraday buying interest. Major Insider Move / SEC Form 4
• Positive Sentiment: Regulatory product win: Abbott received FDA clearance and a CE Mark for its next‑generation Ultreon™ 3.0 AI coronary imaging platform — a tangible medtech catalyst that can support higher‑margin cardiovascular device growth. Ultreon 3.0 FDA clearance and CE Mark
• Positive Sentiment: Analyst support: Citi and BTIG have reiterated buy ratings / bullish price targets (BTIG target $131), which lends institutional backing and may attract value buyers after the pullback. Citi reaffirms buy rating
• Neutral Sentiment: Dividend profile: Abbott remains a large, reliable dividend payer (~$2.52 annualized) that attracts yield‑focused investors and can buoy demand in volatile markets. Dividend/defensive commentary
• Neutral Sentiment: Market tailwinds: Long‑run growth in diagnostics markets (e.g., Saudi Arabia IVD expansion) supports Abbott’s diagnostics franchises but is a longer‑term tailwind rather than an immediate catalyst. Saudi Arabia IVD market report
• Negative Sentiment: Guidance cut and acquisition dilution: Management lowered FY‑26 EPS guidance to $5.38–$5.58, citing ~ $0.20 of dilution from the recently closed Exact Sciences acquisition — the primary driver of the share weakness and the 52‑week low. That explains most of the negative sentiment and analyst target reductions. Q1 earnings and Exact Sciences acquisition fallout

Abbott Laboratories Trading Up 1.1%

Abbott Laboratories stock opened at $93.80 on Wednesday. Abbott Laboratories has a 52-week low of $90.72 and a 52-week high of $139.06. The company has a market cap of $163.37 billion, a P/E ratio of 26.27, a P/E/G ratio of 1.55 and a beta of 0.79. The company has a quick ratio of 1.18, a current ratio of 1.58 and a debt-to-equity ratio of 0.19. The business has a 50-day simple moving average of $105.19 and a two-hundred day simple moving average of $116.55.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings data on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share for the quarter, topping the consensus estimate of $1.14 by $0.01. The firm had revenue of $11.16 billion for the quarter, compared to analysts’ expectations of $10.99 billion. Abbott Laboratories had a net margin of 13.90% and a return on equity of 17.71%. The business’s quarterly revenue was up 7.8% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.09 EPS. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. Analysts predict that Abbott Laboratories will post 5.48 EPS for the current year.

Abbott Laboratories Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be paid a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a dividend yield of 2.7%. The ex-dividend date is Wednesday, April 15th. Abbott Laboratories’s dividend payout ratio (DPR) is currently 70.59%.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.